{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:40:02Z","timestamp":1794638402335,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900215"],"award-info":[{"award-number":["81900215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471175"],"award-info":[{"award-number":["81471175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670201"],"award-info":[{"award-number":["81670201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870161"],"award-info":[{"award-number":["81870161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070221"],"award-info":[{"award-number":["82070221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7162067"],"award-info":[{"award-number":["7162067"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["16JCYBJC42600"],"award-info":[{"award-number":["16JCYBJC42600"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Development of chemoresistance is the main reason for failure of clinical management of multiple myeloma (MM), but the genetic and epigenetic aberrations that interact to confer such chemoresistance remains unknown. In the present study, we find that high steroid receptor coactivator-3 (SRC-3) expression is correlated with relapse\/refractory and poor outcomes in MM patients treated with bortezomib (BTZ)-based regimens. Furthermore, in immortalized cell lines, high SRC-3 enhances resistance to proteasome inhibitor (PI)-induced apoptosis. Overexpressed histone methyltransferase NSD2 in patients bearing a t(4;14) translocation or in BTZ-resistant MM cells coordinates elevated SRC-3 by enhancing its liquid\u2013liquid phase separation to supranormally modify histone H3 lysine 36 dimethylation (H3K36me2) modifications on promoters of anti-apoptotic genes. Targeting SRC-3 or interference of its interactions with NSD2 using a newly developed inhibitor, SI-2, sensitizes BTZ treatment and overcomes drug resistance both in vitro and in vivo. Taken together, our findings elucidate a previously unrecognized orchestration of SRC-3 and NSD2 in acquired drug resistance of MM and suggest that SI-2 may be efficacious for overcoming drug resistance in MM patients.<\/jats:p>","DOI":"10.1038\/s41467-021-21386-y","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:31:41Z","timestamp":1613554301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Targeting NSD2-mediated SRC-3 liquid\u2013liquid phase separation sensitizes bortezomib treatment in multiple myeloma"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2416","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linquan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Lonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-7919","authenticated-orcid":false,"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-1399","authenticated-orcid":false,"given":"Bert W.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0677-8097","authenticated-orcid":false,"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"21386_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"21386_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med"},{"key":"21386_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"21386_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2019.1615051","volume":"18","author":"G Cengiz Seval","year":"2019","unstructured":"Cengiz Seval, G. & Beksac, M. A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. Expert Opin. Drug Saf. 18, 563\u2013571 (2019).","journal-title":"Expert Opin. Drug Saf."},{"key":"21386_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clml.2019.03.025","volume":"19","author":"T Martin","year":"2019","unstructured":"Martin, T. & Huff, C. A. Multiple myeloma: current advances and future directions. Clin. Lymphoma Myeloma Leuk. 19, 255\u2013263 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"21386_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clml.2018.06.015","volume":"18","author":"HN Abramson","year":"2018","unstructured":"Abramson, H. N. The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets. Clin. Lymphoma Myeloma Leuk. 18, 611\u2013627 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"21386_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335\u2013348 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"21386_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fonc.2018.00566","volume":"8","author":"E De Smedt","year":"2018","unstructured":"De Smedt, E. et al. The epigenome in multiple myeloma: impact on tumor cell plasticity and drug response. Front Oncol. 8, 566 (2018).","journal-title":"Front Oncol."},{"key":"21386_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcancer.2017.09.007","volume":"51","author":"M Alzrigat","year":"2018","unstructured":"Alzrigat, M., Parraga, A. A. & Jernberg-Wiklund, H. Epigenetics in multiple myeloma: from mechanisms to therapy. Semin Cancer Biol. 51, 101\u2013115 (2018).","journal-title":"Semin Cancer Biol."},{"key":"21386_CR10","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1158\/1078-0432.CCR-15-1790","volume":"22","author":"C Pawlyn","year":"2016","unstructured":"Pawlyn, C. et al. The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clin. Cancer Res 22, 5783\u20135794 (2016).","journal-title":"Clin. Cancer Res"},{"key":"21386_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.9","volume":"3","author":"F Mirabella","year":"2013","unstructured":"Mirabella, F. et al. MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J. 3, e114 (2013).","journal-title":"Blood Cancer J."},{"key":"21386_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell 128, 693\u2013705 (2007).","journal-title":"Cell"},{"key":"21386_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","volume":"117","author":"E Martinez-Garcia","year":"2011","unstructured":"Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211\u2013220 (2011).","journal-title":"Blood"},{"key":"21386_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/nature09658","volume":"470","author":"H Pei","year":"2011","unstructured":"Pei, H. et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124\u2013128 (2011).","journal-title":"Nature"},{"key":"21386_CR15","doi-asserted-by":"publisher","first-page":"e1004566","DOI":"10.1371\/journal.pgen.1004566","volume":"10","author":"R Popovic","year":"2014","unstructured":"Popovic, R. et al. Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet. 10, e1004566 (2014).","journal-title":"PLoS Genet."},{"key":"21386_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41375-018-0300-0","volume":"33","author":"Z Xie","year":"2019","unstructured":"Xie, Z. et al. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. Leukemia 33, 739\u2013748 (2019).","journal-title":"Leukemia"},{"key":"21386_CR17","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1038\/s41388-018-0393-y","volume":"37","author":"JW Park","year":"2018","unstructured":"Park, J. W., Chae, Y. C., Kim, J. Y., Oh, H. & Seo, S. B. Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis. Oncogene 37, 6212\u20136224 (2018).","journal-title":"Oncogene"},{"key":"21386_CR18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14728222.2012.718330","volume":"16","author":"JC Tien","year":"2012","unstructured":"Tien, J. C. & Xu, J. Steroid receptor coactivator-3 as a potential molecular target for cancer therapy. Expert Opin. Ther. Targets 16, 1085\u20131096 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"21386_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","volume":"15","author":"D Etemadmoghadam","year":"2009","unstructured":"Etemadmoghadam, D. et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 15, 1417\u20131427 (2009).","journal-title":"Clin. Cancer Res."},{"key":"21386_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","volume":"95","author":"CK Osborne","year":"2003","unstructured":"Osborne, C. K. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. 95, 353\u2013361 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"21386_CR21","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/bjc.2013.199","volume":"108","author":"C Palmieri","year":"2013","unstructured":"Palmieri, C. et al. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br. J. Cancer 108, 2039\u20132044 (2013).","journal-title":"Br. J. Cancer"},{"key":"21386_CR22","doi-asserted-by":"crossref","unstructured":"Yi, P., Xia, W., Wu, R. C., Lonard, D. M., Hung, M. C. & O\u2019Malley, B. W. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 27, 274\u2013287 (2013).","DOI":"10.1101\/gad.203760.112"},{"key":"21386_CR23","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/pros.21017","volume":"69","author":"CE Harper","year":"2009","unstructured":"Harper, C. E. et al. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 69, 1668\u20131682 (2009).","journal-title":"Prostate"},{"key":"21386_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s12185-009-0311-8","volume":"89","author":"R Li","year":"2009","unstructured":"Li, R., Chen, Y., Shu, W. X., Chen, Z. & Ke, W. J. Involvement of SRC-3 in deguelin-induced apoptosis in Jurkat cells. Int J. Hematol. 89, 628\u2013635 (2009).","journal-title":"Int J. Hematol."},{"key":"21386_CR25","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"21386_CR26","doi-asserted-by":"crossref","unstructured":"Xie, Y. et al. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Oncogene 39, 922\u2013934 (2019).","DOI":"10.1038\/s41388-019-1037-6"},{"key":"21386_CR27","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41388-019-1037-6","volume":"39","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Oncogene 39, 922\u2013934 (2020).","journal-title":"Oncogene"},{"key":"21386_CR28","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-17-2483","volume":"24","author":"L Huang","year":"2018","unstructured":"Huang, L. et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A Expression. Clin. Cancer Res. 24, 3366\u20133376 (2018).","journal-title":"Clin. Cancer Res."},{"key":"21386_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41232-020-00113-y","volume":"40","author":"N Hosen","year":"2020","unstructured":"Hosen, N. Integrins in multiple myeloma. Inflamm. Regen. 40, 4 (2020).","journal-title":"Inflamm. Regen."},{"key":"21386_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrclinonc.2009.219","volume":"7","author":"O Gojis","year":"2010","unstructured":"Gojis, O. et al. The role of SRC-3 in human breast cancer. Nat. Rev. Clin. Oncol. 7, 83\u201389 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"21386_CR31","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1073\/pnas.1604274113","volume":"113","author":"X Song","year":"2016","unstructured":"Song, X. et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc. Natl Acad. Sci. USA 113, 4970\u20134975 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21386_CR32","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1073\/pnas.0400782101","volume":"101","author":"AI Su","year":"2004","unstructured":"Su, A. I. et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 101, 6062\u20136067 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21386_CR33","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1158\/1078-0432.CCR-12-0531","volume":"18","author":"K Boucher","year":"2012","unstructured":"Boucher, K. et al. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin. Cancer Res. 18, 6155\u20136168 (2012).","journal-title":"Clin. Cancer Res."},{"key":"21386_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrc2695","volume":"9","author":"J Xu","year":"2009","unstructured":"Xu, J., Wu, R. C. & O\u2019Malley, B. W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 9, 615\u2013630 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"21386_CR35","doi-asserted-by":"publisher","first-page":"21848","DOI":"10.1074\/jbc.M603772200","volume":"281","author":"H Wu","year":"2006","unstructured":"Wu, H. et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J. Biol. Chem. 281, 21848\u201321856 (2006).","journal-title":"J. Biol. Chem."},{"key":"21386_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1745-7254.2006.00315.x","volume":"27","author":"J Yan","year":"2006","unstructured":"Yan, J., Tsai, S. Y. & Tsai, M. J. SRC-3\/AIB1: transcriptional coactivator in oncogenesis. Acta Pharm. Sin. 27, 387\u2013394 (2006).","journal-title":"Acta Pharm. Sin."},{"key":"21386_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.tcb.2018.02.004","volume":"28","author":"S Boeynaems","year":"2018","unstructured":"Boeynaems, S. et al. Protein phase separation: a new phase in cell biology. Trends Cell Biol. 28, 420\u2013435 (2018).","journal-title":"Trends Cell Biol."},{"key":"21386_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s11427-020-1702-x","volume":"63","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Liquid-liquid phase separation in biology: mechanisms, physiological functions and human diseases. Sci. China Life Sci. 63, 953\u2013985 (2020).","journal-title":"Sci. China Life Sci."},{"key":"21386_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12551-020-00680-x","volume":"12","author":"T Yoshizawa","year":"2020","unstructured":"Yoshizawa, T., Nozawa, R. S., Jia, T. Z., Saio, T. & Mori, E. Biological phase separation: cell biology meets biophysics. Biophys. Rev. 12, 519\u2013539 (2020).","journal-title":"Biophys. Rev."},{"key":"21386_CR40","doi-asserted-by":"crossref","unstructured":"Shin, Y. & Brangwynne, C. P. Liquid phase condensation in cell physiology and disease. Science 357, eaaf4382 (2017)","DOI":"10.1126\/science.aaf4382"},{"key":"21386_CR41","doi-asserted-by":"crossref","unstructured":"Strom, A. R. & Brangwynne, C. P. The liquid nucleome-phase transitions in the nucleus at a glance. J Cell Sci. 132, jcs.235093 (2019).","DOI":"10.1242\/jcs.235093"},{"key":"21386_CR42","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1126\/science.aaz4427","volume":"368","author":"IA Klein","year":"2020","unstructured":"Klein, I. A. et al. Partitioning of cancer therapeutics in nuclear condensates. Science 368, 1386\u20131392 (2020).","journal-title":"Science"},{"key":"21386_CR43","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1158\/0008-5472.CAN-16-2982","volume":"77","author":"AD Rohira","year":"2017","unstructured":"Rohira, A. D. et al. Targeting SRC coactivators blocks the tumor-initiating capacity of cancer stem-like cells. Cancer Res 77, 4293\u20134304 (2017).","journal-title":"Cancer Res"},{"key":"21386_CR44","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"21386_CR45","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"21386_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679\u2013686 (2010).","journal-title":"Blood"},{"key":"21386_CR47","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.1002\/anie.201602558","volume":"55","author":"X Bai","year":"2016","unstructured":"Bai, X. et al. Development of a DNA-templated peptide probe for photoaffinity labeling and enrichment of the histone modification reader. Proteins Angew. Chem. Int Ed. Engl. 55, 7993\u20137997 (2016).","journal-title":"Proteins Angew. Chem. Int Ed. Engl."},{"key":"21386_CR48","doi-asserted-by":"publisher","first-page":"353ra113","DOI":"10.1126\/scitranslmed.aad8949","volume":"8","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci. Transl. Med 8, 353ra113 (2016).","journal-title":"Sci. Transl. Med"},{"key":"21386_CR49","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1182\/blood-2014-03-557298","volume":"124","author":"Z Liu","year":"2014","unstructured":"Liu, Z. et al. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124, 2061\u20132071 (2014).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21386-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:48:09Z","timestamp":1669960089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21386"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21386-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.W.O, D.M.L., and J.W. all hold equity positions and receive research funding from Coactigon, Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1022"}}